Angiogenesis in Lung Cancer: Understanding the Roles of Growth Factors

Author:

Ngaha Tchawe Yvan Sinclair12,Zhilenkova Angelina V.1,Essogmo Freddy Elad1,Uchendu Ikenna K.13,Abah Moses Owoicho1ORCID,Fossa Lionel Tabola4,Sangadzhieva Zaiana D.1,D. Sanikovich Varvara1,S. Rusanov Alexander1,N. Pirogova Yuliya1,Boroda Alexander1,Rozhkov Alexander1,Kemfang Ngowa Jean D.5,N. Bagmet Leonid1,I. Sekacheva Marina1

Affiliation:

1. Institute for Personalized Oncology, Center for Digital Biodesign and Personalized Healthcare, First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University), 8-2 Trubetskaya str., Moscow 119991, Russia

2. Department of Public Health, James Lind Institute, Rue de la Cité 1, 1204 Geneva, Switzerland

3. Medical Laboratory Science Department, Faculty of Health Science and Technology, College of Medicine, University of Nigeria, Enugu Campus, Enugu 410001, Nigeria

4. Department of Oncology, Bafoussam Regional Hospital, Bafoussam 980, Cameroon

5. Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Yaounde 1364, Cameroon

Abstract

Research has shown the role of growth factors in lung cancer angiogenesis. Angiogenesis promotes lung cancer progression by stimulating tumor growth, enhancing tumor invasion, contributing to metastasis, and modifying immune system responses within the tumor microenvironment. As a result, new treatment techniques based on the anti-angiogenic characteristics of compounds have been developed. These compounds selectively block the growth factors themselves, their receptors, or the downstream signaling pathways activated by these growth factors. The EGF and VEGF families are the primary targets in this approach, and several studies are being conducted to propose anti-angiogenic drugs that are increasingly suitable for the treatment of lung cancer, either as monotherapy or as combined therapy. The efficacy of the results are encouraging, but caution must be placed on the higher risk of toxicity, outlining the importance of personalized follow-up in the management of these patients.

Publisher

MDPI AG

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3